interesting stuff, seems to be protective using receptor and anti cancer RAS inhibitor mechanism.
No expert but although a currently approved product it’s for blood pressure control, to be used for cancer and in combo with dox would require trials, so being first to market is relevant. Off-label use wouldn’t be a feasible strategy.
RAS inhibitor may be selective and promising anti-cancer in certain cancer indications, you can see the two groups below one performing well and group B (perhaps not impacted by RAS) which was underwhelming anti-cancer and x100 dose of Bisantrene.
Included Bisantrene as a comparative, note the IC50
dosing.
http://dx.doi.org/10.1177/1470320319851310
- Forums
- ASX - By Stock
- Cardioprotection thread
interesting stuff, seems to be protective using receptor and...
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M |
Open | High | Low | Value | Volume |
$1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 92 | $1.83 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.87 | 3472 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5300 | 1.810 |
1 | 8722 | 1.800 |
1 | 1059 | 1.790 |
4 | 10695 | 1.750 |
2 | 8147 | 1.730 |
Price($) | Vol. | No. |
---|---|---|
1.865 | 3472 | 1 |
1.880 | 2500 | 1 |
1.940 | 5148 | 2 |
1.945 | 3014 | 1 |
1.950 | 12000 | 1 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |